


1617



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
GROUP ART 1617

In re

Patent Application of

Richard B. Mazess

Serial No. 09/995,911

Filed: November 28, 2001

Confirmation No.: 4126

Examiner: not yet assigned

"TREATMENT OF HYPERPROLIFERTIVE
DISEASES USING ACTIVE VITAMIN D
ANALOGUES"

I, Leslie Lindsay, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope with sufficient postage addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on the date of my signature.

Leslie Lindsay
Signature

05 Aug. 2002
Date of Signature

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97-1.98 WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING DATE OF FIRST OFFICE ACTION**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR § 1.97-1.98, Applicants submit this second supplemental information disclosure statement and a listing of documents on Form PTO-1449. Also enclosed is a copy of each cited publication and Certification Under 37 CFR §1.97(e).

Citation of these references is respectfully requested.

This second supplemental information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits whichever event occurs last.

Applicants respectfully request that the documents be considered by the Examiner, be made of record in the present application and that an initialed copy of Forms PTO-1449 be returned in accordance with MPEP §609.

Please charge Deposit Account No. 50-0842 for any shortage or overpayment of any necessary fee associated with the filing of this information disclosure statement.

Respectfully submitted,



Jeffrey D. Peterson
Reg. No. 49,038

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
(608) 257-3501